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over expression. The significant differences in OS and 
DFS (P = 0.008 and 0.004) were noticed according to VL, 
wherein 100% DFS was found for patients with higher 
VL. According to P16 expression, significant difference 
was found only for OS (P = 0.020). In multivariate analy-
sis, VL (P = 0.045; HR = 2.795; CI 0.121–1.060) and the 
level of smoking (P = 0.023, HR = 2.253; CI 1.124–4.514) 
were independent factors affecting DFS of HPV16-positive 
patients.
Conclusion On the basis of viral load, it is possible to 
differentiate prognosis of patients with HPV16-positive 
HNSCCs. In this subgroup, viral load has stronger prognos-
tic potential than P16 expression.
Keywords HNSCCs · HPV16 · Viral load · P16 
expression · Prognosis
Introduction
Epidemiological studies have shown important role of high-
risk (HR) human papillomavirus (HPV) in development of 
some types of squamous cell carcinomas (SCCs) of head 
and neck (HN) (Castellsagué et al. 2017). This infection 
(mostly HPV16) is predominantly observed in cancers of 
the oral cavity, oropharynx and larynx (Castellsagué et al. 
2017). The meta-analyses, covering 99 studies, have found 
more favourable prognosis for patients with HPV-positive 
HNSCCs than for those without infection (Ragin and Taioli 
2007; Dayyani et al. 2010; O’Rorke et al. 2012; Liu et al. 
2016). However, the values of the hazard ratios from these 
analyses 0.30 (O’Rorke et al. 2012)–0.62 (Ragin and Taioli 
2007) show that in more than 40% of HPV-infected patients 
progression of cancer disease is observed. Their identifica-
tion is particularly important nowadays, because of ongoing 
Abstract 
Purpose To evaluate the impact of HPV16 load (VL—the 
number of virus genome copies per cell) and P16 expres-
sion on prognosis of patients with squamous cell carcinomas 
(SCCs) of head and neck (HN).
Materials and methods  HPV16 presence was assessed in 
the group of 109 patients with HNSCCs by quantitative pol-
ymerase chain reaction (qPCR). VL (assessed by qPCR) and 
P16 expression (evaluated by immunohistochemistry) were 
analysed only in the subgroup of HPV16-positive tumours. 
These features were correlated with 5-year overall survival 
(OS) and disease-free survival (DFS).
Results HPV16 infection was found in 36 tumours 
(33.0%). Virus-positive patients had better OS and DFS 
than those without infection (P = 0.041 and 0.005). Among 
HPV16-positive HNSCCs, 18 (50.0%) had higher VL 
(median value > 6764.3 copies/cell) and 25 (73.5%) P16 
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trials concerning de-escalation of anticancer treatment in 
patients with HPV-positive HNSCCs (Mirghani et al. 2015).
Researchers attempt to identify patients with HPV-posi-
tive HNSCCs and worse prognosis on the basis of viral load 
(VL—the number of HPV16 copies expressed per sample 
or per single cell). However, results of these studies are 
ambiguous, as in some of them positive prognosis is associ-
ated with higher VL (Mellin et al. 2002; Cohen et al. 2008; 
Worden et al. 2008; Holzinger et al. 2012), while in others, 
opposite correlation is found (Huang et al. 2014). On the 
other hand, some authors have shown significant positive 
correlation between VL and P16 overexpression (Rödel et al. 
2015) and between higher VL and expression of HPV E6/E7 
mRNA (indicating transcriptionally active HPV infection) 
(Jung et al. 2010; Holzinger et al. 2012; Deng et al. 2013). 
Our suggestion is that high VL reflects active infection. 
Hence, the present study aims to: (1) assess HPV16 pres-
ence by amplification of virus E6 gene fragment in quantita-
tive polymerase chain reaction (qPCR) in 109 patients with 
HNSCCs from Cracow area and (2) analyse the influence of 
VL (HPV16 genome copies calculated per single cell) and 
P16 expression on 5-year overall survival (OS) and 5-year 




The study was performed in 109 patients with SCCs of oral 
cavity, oropharynx, hypopharynx and larynx, with no distant 
metastasis at the moment of diagnosis and treated, between 
2007 and 2014, in Maria Sklodowska-Curie Memorial 
Cancer Center and Institute of Oncology, Cracow Branch. 
The study was approved by the Ethical Committee at the 
Regional Medical Chamber in Cracow (Poland) on 19 Sep-
tember 2012 (109/KBL/OIL/2012) on 19 September 2012 
(109/KBL/OIL/2012). No informed consents from patients 
were required, because during the study no direct contact 
with patients and use of personal data were necessary. All 
samples were anonymized.
Histopathological verification of formalin‑fixed 
and paraffin‑embedded cancer specimens, DNA 
isolation
For 109 patients, formalin-fixed and paraffin-embedded 
(FFPE) cancer specimens (obtained during surgery or 
biopsy) were collected. They have been subjected to his-
topathological reverification, which included: tumour his-
tology (squamous cell carcinoma), histologic grade and 
degree of keratinization. Selected for further analysis were 
these FFPE, in which tumour component covered > 50% 
of the slide area.
From FFPE selected by pathologists DNA was iso-
lated using ReliaPrep™ FFPE gDNA Miniprep System 
(Promega, Madison, USA) based on manufacturer’s sug-
gestions with our own modification. The procedure was 
detailed previously (Biesaga et al. 2016).
HPV16 presence and its load
The HPV16 presence was determined on the basis of 
amplification of 81-bp fragment of virus E6 gene with 
primers (F: GAG AAC TGC AAT GTT TCA GGA CC, 
R: TGT ATA GTT GTT TGC AGC TCT GTG C) and 
TaqMan probe (6FAM-CAG GAG CGA CCC AGA AAG 
TTA CCA CAG TT-TAMRA), synthesized by Thermo 
Fisher Scientific, Waltham, USA, as previously described 
in detail (Biesaga et al. 2012). In brief, amplification was 
carried out in a 25 µl mixture containing: 12.5 µl of Fast 
Universal PCR Master Mix (2 X), 100 nM of each primer, 
300 nM of probe and 80 ng of DNA template. Thermal 
cycling (ViiA 7, Thermo Fisher Scientific, Waltham, USA) 
consisted of initial denaturation (20 s, 95°C) and 45 cycles 
of 3 s at 95 °C and 30 s at 60 °C. Each sample was tested 
in duplicate.
To each sample set analysed for HPV16 detection, a 
series of tenfold dilutions of HPV16 plasmid (ATCC, 
USA), containing from 5 × 108 to 5 × 1012 HPV16 cop-
ies, was added. This allowed to draw a standard curve 
(Ct vs the number of virus copies), on which Ct values 
obtained for clinical samples were plotted and the number 
of HPV16 genome copies was calculated. Additionally, 
to evaluate VL, a number of cells in each sample were 
analysed. For this purpose, each DNA was subjected to 
qPCR for amplification of 139-bp fragment of β-actin gene 
using  TaqMan® Gene Expression Assay (Thermo Fisher 
Scientific, Waltham, USA), with mix of specific primers 
and MGB probe. Amplification was carried out in reaction 
volume of 20 µl, containing: 10 µl of Fast Universal PCR 
Master Mix (2 X) (Thermo Fisher Scientific, Waltham, 
USA), 1 µl of TaqMan Gene Expression Assay and 50 ng 
of DNA template. qPCR was initiated with 20-s incubation 
at 95 °C; then, 40 cycles at 95 °C for 1 s and 60 °C for 20 s 
were applied (ViiA 7, Thermo Fisher Scientific, Waltham, 
USA). Two replicates were used per sample. To generate 
standard curve and calculate the number of cells in sample, 
for each assay, serial tenfold dilutions of human genomic 
DNA (Roche Diagnostics, GmbH, Germany), containing 
from 1 to 114,200 β-actin copies, were added. HPV16 
VL was calculated as the number of virus copies per cell, 
assuming that two copies of β-actin gene correspond to 
one cell (Mellin et al. 2002).
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P16 immunostaining
P16 immunostaining was performed in the subgroup of 
HPV16-positive tumours using  CINtec® Histology Kit 
(Roche, Heidelberg, Germany) according to the manufac-
turer’s procedure. Briefly, after deparaffinization and rehy-
dration, antigen retrieval (96 °C for 10 min) and quenching 
of endogenous peroxidases procedures were applied. Incuba-
tions with primary antibody and visualization system were 
carried out for 30 min. The reaction was visualized with 
DAB as a chromogen. Slides were counterstained using 
Mayer’s haematoxylin. To each set of staining-negative 
(absence of primary antibody) and staining-positive (cervi-
cal cancer with known P16 strong reaction) controls were 
added. Immunopositivity was defined according to Lewis 
et al. (2012) as follows: > 75% of positive staining cells 
or > 50% staining with > 25% confluent areas of positive 
staining (Fig. 1).
Statistical analysis
Descriptive statistics were used to determine mean and 
median of continuous variables and standard errors of means 
(SE). Student’s t test was applied to establish the significance 
of differences between means. Associations between cat-
egorical variables were analysed using Pearson Chi-square 
test. To analyse prognostic potential, two endpoints were 
adopted: OS (time from the end of therapy until death from 
any cause within 5 years after completing the treatment) 
and DFS (time from the end of therapy until the first docu-
mented evidence of recurrent disease—treatment failure, 
locoregional recurrence, distant metastasis, within 5 years 
after completing the treatment). We decided to define OS 
and DFS from the date of treatment completing and not from 
the date of initial diagnosis in order to eliminate differences 
between individual patients in the period of time between 
diagnosis and the start of treatment and in the total treatment 
time. Survival curves were obtained using Kaplan–Meier 
estimates, and differences between groups were tested by the 
log-rank test. Univariate and multivariate survival analyses 
were carried out according to the Cox proportional hazards 
model. Multivariate analysis included all the parameters for 
which in univariate analysis, statistically significant influ-
ence on survival was observed. All statistical tests were two-
sided, and P < 0.050 was considered significant. Statisti-




The mean and median age of 109 patients were 57.3 ± 0.9 
and 58 years. There were 9 (8.3%) patients with tumours 
in stage II, 22 (20.2%) in III and 78 (71.6%) in IV. The 
detailed patients and tumour characteristics are summarized 
in Table 1.
Most patients (46) were subjected to concurrent chemo-
radiotherapy (CRT) as a definitive or post-operative treat-
ment. The total dose of radiotherapy (RT) ranged from 28 to 
70 Gy (mean 66.1 Gy ± 1.5), applied in 14–35 fractions of 
2.0–2.2 Gy. During RT, cisplatin (CisPt) was administrated 
according to two schemes: (1) 100 mg CisPt/m2 every 3rd 
week of RT in 2–3 courses or (2) 40 mg CisPt/m2 every 
week of RT in 3–6 courses (depending on patient’s condi-
tion and the severity of early normal tissue reactions). For 38 
patients, RT (alone or post-operative) was applied (total dose 
of 20.0–74.0 Gy, fraction dose: 1.8–4.0 Gy, number of frac-
tions: 5–40). In turn, 25 patients were treated with induction 
Fig. 1  Immunohistochemical staining of P16 using  CINtec® Histol-
ogy Kit (Roche, Heidelberg, Germany) in formalin-fixed paraffin-
embedded samples of head and neck cancers. a Tumour with P16 
overexpression defined by Lewis et  al. (2012) as follows: > 75% of 
positive staining cells or > 50% staining with > 25% confluent posi-
tive staining areas. b Tumour with lack of P16 overexpression
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Table 1  Clinical and 
histopathological features 
according to HPV16 presence 
assessed by amplification of 
virus E6 gene fragment in 
quantitative polymerase chain 
reaction in the group of 109 
patients with squamous cell 
carcinomas of head and neck
Feature All N (%)a HPV16+ N (%) HPV16− N (%) P value (test χ2)
All 109 (100.0) 36 (33.0) 73 (67.0)
Age
 ≤ 58 yearsb 51 (46.8) 12 (33.3) 39 (53.4) 0.048
 > 58 years 58 (53.2) 24 (66.7) 34 (46.6)
Gender
 Female 22 (20.2) 9 (25.0) 13 (17.8) 0.379
 Male 87 (79.8) 27 (75.0) 60 (82.2)
Status in the Karnofsky scale
 ≤ 80% 49 (45.0) 15 (41.7) 34 (46.6) 0.628
 > 80% 60 (55.0) 21 (58.3) 39 (53.4)
Localization
 Oral cavity 24 (22.0) 6 (16.6) 18 (24.7) 0.501
 Oropharynx 68 (62.4) 26 (72.2) 42 (57.5)
 Hypopharynx 7 (6.4) 2 (5.6) 5 (6.8)
 Larynx 10 (9.2) 2 (5.6) 8 (11.0)
T stage
 1 2 (1.8) 0 (0.0) 2 (2.7) 0.211
 2 24 (22.0) 9 (25.0) 15 (20.6)
 3 60 (55.1) 23 (63.9) 37 (50.7)
 4 23 (21.1) 4 (11.1) 19 (26.0)
N stage
 0 19 (17.4) 5 (13.9) 14 (19.1) 0.820
 1 18 (16.5) 5 (13.9) 13 (17.8)
 2 61 (56.0) 22 (61.1) 39 (53.4)
 3 11 (10.1) 4 (11.1) 7 (9.6)
Grade
 1 40 (36.7) 12 (33.3) 28 (38.4) 0.641
 2 57 (52.3) 21 (58.3) 36 (49.3)
 3 12 (11.0) 3 (8.3) 9 (12.3)
Keratinization
 Yes 62 (56.9) 15 (41.7) 47 (64.0) 0.024
 No 47 (43.1) 21 (58.3) 26 (36.0)
The level of smoking—Brinkman  indexc
 ≤  520b 54 (49.5) 20 (55.6) 34 (46.6) 0.378
 > 520 55 (50.5) 16 (67.6) 39 (53.4)
The level of  drinkingd
 Low 50 (45.9) 20 (55.6) 30 (41.1) 0.154
 High 59 (54.1) 16 (44.4) 43 (58.9)
Treatment
 Definitive CRT or surgery + CRT 46 (42.2) 19 (52.8) 27 (37.0) 0.289
 Definitive RT or surgery + RT 38 (34.9) 10 (27.8) 28 (38.3)
 Induction CT + definitive RT 25 (22.9) 7 (19.4) 18 (24.7)
Treatment outcome
 Regression of cancer disease 71 (65.1) 28 (77.8) 43 (58.9) 0.151
 Treatment failure 6 (5.5) 1 (2.8) 5 (6.9)
 Local recurrence 22 (20.2) 6 (16.7) 16 (21.9)
 Distant metastases 10 (9.2) 1 (2.8) 9 (12.3)
Survival
 Alive at the last follow-up 74 (67.9) 28 (77.8) 46 (63.0) 0.291
 Death from cancer disease 19 (17.4) 4 (11.1) 15 (20.6)
 Death from others reasons 16 (14.7) 4 (11.1) 12 (16.4)
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chemotherapy (CisPt + 5-fluorouracil + taxanes), followed 
by RT (total dose: 20–70 Gy, fraction dose: 2–4 Gy, number 
of doses: 5–35).
The mean follow-up time was 37.8  months 
(1–114 months). Among 109 patients, 74 were alive at the 
time of the study, 19 died from cancer disease and 16 from 
others reasons, mainly cardiovascular disease. Regression 
of cancer was noticed in 71 persons (65.1%) and progres-
sion (treatment failure, locoregional recurrence, distant 
metastases) occurred in 38 patients (34.9%), from 0 to 
88 months after completing treatment (mean and median: 
16.3 months ± 3.2 and 10 months). Because of low number 
of distant metastasis (n = 10), we did not decide to assess 
metastasis-free survival.
HPV16 infection, viral load, P16 expression—
correlation with clinical and histopathological data
Among 109 tumours, HPV16 infection (assessed on the 
basis of E6 gene fragment amplification) was found in 36 
cases (33.0%) (Table 1). Infection was significantly more 
common in older patients, as well as in oropharynx and 
in non-keratinizing tumours. The distribution of HPV16-
positive and HPV16-negative tumours was not significantly 
related to other clinical features studied.
In the subgroup of 36 HPV16-positive cancers, the mean 
and median values of VL were 90 407.8 copies/cell ± 62 
493.7 (SE) and 6764.3 copies/cell (range 0.9–2244, 936.0). 
HPV16-positive tumours were grouped, according to VL 
median value, as those with lower (≤ 6764.3 copies/cell, 
n = 18) and with higher VL (> 6764.3 copies/cell, n = 18) 
(Table 2). Most patients having tumours with higher VL did 
not suffer from alcohol abuse and were treated with CRT. 
No other significant relations were found between VL and 
clinical or histopathological features.
Due to lack of material in 2 paraffin blocks, P16 expres-
sion was evaluated in the subgroup of 34 HPV16-positive 
patients (assessed by E6 gene fragment amplification). There 
were 25 (73.5%) tumours with P16 overexpression and 9 
(26.5%) without high protein expression (Table 2). P16 over-
expression was significantly more frequent in cancers char-
acterized by higher VL, and all cancers without P16 overex-
pression were characterized by lower VL. The distribution 
of tumours with P16 overexpression was also significantly 
associated with site of cancer localization, lymph node status 
and the level of drinking.
HPV16 infection, viral load, P16 expression—survival 
analysis
For 109 patients, OS and DFS were 44.4 and 60.9%, respec-
tively, and were significantly higher in patients with HPV16 
infection (Table 3). Significantly better OS was also found 
for females and lower T and N stages. In turn, significantly 
higher DFS was noticed for females, patients with lower 
levels of smoking and drinking and with lower T stage and 
lower grade. All variables suggesting significantly better OS 
and DFS in univariate analysis were included in multivariate 
analysis. For OS, female gender, lower N stage and HPV16 
presence were independent favourable prognostic factors 
(Table 4). For DFS, such factors proved to be: lower T stage, 
lower level of smoking and HPV16 presence.
Separate survival analysis was also performed in the sub-
group of 36 patients with HPV16 positivity (assessed by E6 
gene fragment amplification). Better OS (Fig. 2a) and DFS 
(Fig. 2b) was significantly related to higher VL, wherein 
all patients with higher VL (n = 18) survived 5 years with-
out any evidence of disease. Significantly higher OS was 
also found for patients having tumours with P16 overex-
pression than for those without overexpression (Fig. 2c). In 
case of DFS, this relation was similar, though not significant 
(Fig. 2d). OS was not significantly dependent on all epide-
miological, clinical and histopathological features tested. In 
turn, higher DFS was also noticed for light smokers (95.0%) 
compared to heavy smokers (68.8%) (P = 0.034), as well as 
for patients with better performance status (95.2 vs 66.7%) 
(P = 0.021). Other features did not significantly influence 
DFS. Multivariate analysis was not performed for OS, 
because VL and P16 expression—two parameters, which 
significantly affected OS in univariate analysis—were sig-
nificantly correlated with each other (Table 2). For DFS, in 
multivariate analysis three parameters were included: VL, 
the level of smoking and performance status. VL and the 
level of smoking were two independent prognostic factors 
for DFS of patients with HPV16 positivity (Table 4).
Discussion
In the present study, among 109 patients with HNSCCs, 
HPV16 infection was found in 36 (33%) cases. It was also 
shown that using HPV16 load (the number of viral genome 
copies per single cell), it is possible to stratify patients with 
Table 1  (continued) a Row percentage
b Median value
c Number of cigarettes per day × years of smoking
d Low level of drinking—no alcohol and occasional drinkers (at most two drinks a day, especially with a 
meal) high level of drinking—more than 15 drinks of high percentage alcohol in a week and alcoholics
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Table 2  Clinical and histopathological features of 36 patients with HPV16-positive HNSCC (assessed by amplification of E6 gene fragment) 















P value (test χ2)
All 18 (50.0) 18 (50.0) 9 (26.5) 25 (73.5)
Age
 ≤ 58 yearsa 6 (33.3) 6 (33.3) 1.000 4 (44.4) 7 (28.0) 0.366
 > 58 years 12 (66.7) 12 (66.7) 5 (55.6) 18 (72.0)
Gender
 Female 4 (22.2) 5 (27.8) 0.700 1 (11.1) 17 (68.0) 0.223
 Male 14 (77.2) 13 (72.2) 8 (88.9) 8 (32.0)
Status in the Karnofsky scale
 ≤ 80% 9 (50.0) 6 (33.3) 0.310 3 (33.3) 10 (40.0) 0.724
 > 80% 9 (50.0) 12 (66.7) 6 (66.7) 15 (60.0)
Localization
 Oral cavity 3 (16.7) 3 (16.7) 0.202 2 (22.2) 4 (16.0) 0.003
 Oropharynx 11 (61.1) 15 (83.3) 3 (33.4) 21 (84.0)
 Hypopharynx 2 (11.1) 0 (0.0) 2 (22.2) 0 (0.0)
 Larynx 2 (11.1) 0 (0.0) 2 (22.2) 0 (0.0)
T stage
 1 0 (0.0) 0 (0.0) 0.985 0 (0.0) 0 (0.0) 0.861
 2 4 (22.2) 5 (27.8) 3 (33.3) 6 (24.0)
 3 12 (66.7) 11 (61.1) 5 (55.6) 16 (64.0)
 4 2 (11.1) 2 (11.1) 1 (11.1) 3 (12.0)
N stage
 0 4 (22.2) 1 (5.6) 0.072 4 (44.4) 1 (4.0) 0.016
 1 0 (0.0) 5 (27.8) 0 (0.0) 5 (20.0)
 2 12 (66.7) 10 (55.6) 5 (55.6) 16 (64.0)
 3 2 (11.1) 2 (11.1) 0 (0.0) 3 (12.0)
Grade
 1 7 (38.9) 5 (27.8) 0.700 4 (44.4) 8 (32.0) 0.597
 2 10 (55.6) 11 (61.1) 5 (55.6) 15 (60.0)
 3 1 (5.5) 2 (11.1) 0 (0.0) 2 (8.0)
Keratinization
 Yes 7 (38.9) 8 (44.4) 0.735 5 (55.6) 15 (60.0) 0.816
 No 11 (61.1) 10 (55.6) 4 (44.4) 10 (40.0)
The level of smoking—Brinkman  indexc
 ≤  520a 8 (44.4) 12 (66.7) 0.180 4 (44.4) 16 (64.0) 0.307
 > 520 10 (55.6) 6 (33.3) 5 (55.6) 9 (36.0)
The level of  drinkingd
 Low 4 (22.2) 16 (88.9) 0.000 1 (11.1) 18 (72.0) 0.002
 High 14 (77.8) 2 (11.1) 8 (88.9) 7 (28.0)
Viral load
 ≤ 6764.3 copies/cella – – 9 (100.0) 7 (28.0) 0.000
 > 6764.3 copies/cell – – 0 (0.0) 18 (72.0)
Treatment
 Definitive CRT or surgery + CRT 5 (27.8) 14 (77.8) 0.009 3 (33.3) 16 (64.0) 0.283
 Definitive RT or surgery + RT 7 (38.9) 3 (16.7) 4 (44.4) 6 (24.0)
 Induction CT + definitive RT 6 (33.3) 1 (5.5) 2 (22.2) 3 (12.0)
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head and neck cancers and HPV16 positivity according to 
their prognosis. We have found, to the best of our knowledge 
for the first time, 100% DFS for patients with higher VL 
(median > 6764.3 copies/cell) (Fig. 2b). Moreover, mul-
tivariate analysis revealed this biomarker to be, beside the 
level of smoking, an independent prognostic factor for DFS 
of HPV16-positive patients. P16 expression represents less 
powerful prognostic factor than VL, because in this case 
statistical significance was achieved only for OS (Fig. 2c, 
d). Similar results were presented by Rödel et al. (2015), 
who in the group of 95 patients with anal HPV16-positive 
SCCs have shown significantly better local control and OS 
for patients with high VL and P16 overexpression. How-
ever, in their paper, VL and P16 expression did not signifi-
cantly influence cancer-specific survival. Reports concern-
ing HNSCCs have also shown significantly higher DFS for 
patients with tumours characterized by higher VL (Mellin 
et al. 2002; Cohen et al. 2008; Worden et al. 2008; Holz-
inger et al. 2012). We hypothesize that positive prognosis 
of patients with higher VL may be related to stimulation of 
immune response in the presence of transcriptionally active 
HPV infection. This hypothesis is supported by some studies 
in which correlations between higher VL and overproduction 
of circulating antibodies against plasma virus-like particles 
or antibodies against HPV16 oncoproteins E6 and E7 (Kre-
imer et al. 2005) and between higher VL and expression of 
HPV E6/E7 mRNA were found (Jung et al. 2010; Holzinger 
et al. 2012; Deng et al. 2013). On the other hand, in the pre-
sent paper we have found, like other authors (Chang et al. 
2014; Sannigrahi et al. 2016), significant positive relation 
between HPV16 VL and P16 expression (Table 2). In normal 
cells, P16 plays a role as a regulator of cell cycle, through, in 
brief, inhibition of phosphorylation of Rb family members 
(Serrano 1997). Because E7 oncoprotein (produced after 
integration of viral genome into the host genome) degrades 
Rb, P16 overexpression is observed in cells with transcrip-
tionally active infection (Lewis et al. 2012). All these facts 
suggest higher activity of E6 and E7 in cells harbouring 
higher VL and stronger stimulation of systemic and local 
immune response. However, results of some studies show-
ing positive correlation between E6 expression and higher 
risk of recurrence contradict this hypothesis (Khwaja et al. 
2016). It was also suggested that oropharyngeal SCCs with 
HPV infection were more likely to be B7-H1 positive (B7-
H1 is involved in B7-H1/PD-1 signalling pathway of host 
immune suppression), which allowed to avoid inflammatory 
immune responses (Ukpo et al. 2013).
Despite above-mentioned results showing significant 
correlation between HPV16 VL and patients survival and 
hypothesis explaining these observations, prognostic poten-
tial of HPV16 VL in patients with HNSCCs is not clearly 
established. First of all, some authors (Huang et al. 2014) 
have shown opposite results, i.e. significantly higher rate 
of distant metastasis in patients with higher VL of HPV16 
and HPV18. Besides, there are some controversies related 
to VL cut-off point which should be applied for optimal 
separation of survival curves. In the present paper, we have 
used median value (6764.3 copies/cell), in others it ranged 
from 15 (Huang et al. 2014) to 500 copies/cell (Cohen et al. 
2008). These differences can be partly explained by analysis, 
in most of above-mentioned papers, of small patient group 
that was heterogeneous in respect to cancer localization. 
Besides, qPCR (used for VL estimation) may produce some 
divergent results, due to necessity of generation of reliable, 















P value (test χ2)
Treatment outcome
 Regression of cancer disease 12 (66.8) 16 (88.9) 0.504 6 (66.7) 21 (84.0) 0.140
 Treatment failure 1 (5.5) 2 (11.1) 0 (0.0) 1 (4.0)
 Local recurrence 4 (22.2) 0 (0.0) 3 (33.3) 2 (8.0)
 Distant metastases 1 (5.5) 0 (0.0) 0 (0.0) 1 (4.0)
Survival
 Alive at the last follow-up 12 (66.7) 16 (88.9) 0.102 3 (33.3) 19 (76.0) 0.072
 Death from cancer disease 4 (22.2) 0 (0.0) 3 (33.3) 3 (12.0)
 Death from others reasons 2 (11.1) 2 (11.1) 3 (33.3) 3 (12.0)
a Median value
b Row percentage
c Number of cigarettes per day × years of smoking
d Low level of drinking—no alcohol and occasional drinkers (at most two drinks a day, especially with a meal) high level of drinking—more than 
15 drinks of high percentage alcohol in a week and alcoholics
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Table 3  Univariate Cox proportional hazard model for 5-year overall and disease-free survival of 109 patients with squamous cell carcinoma of 
head and neck
HR hazard ratio, CI confidence interval
a Row percentage
b Median values
c Number of cigarettes per day × years of smoking
d Low level of drinking—no alcohol and occasional drinkers (at most two drinks a day, especially with a meal) high level of drinking—more than 
15 drinks of high percentage alcohol in a week and alcoholics
Overall survival Disease-free survival
Response N (%)a HR 95% CI Log-rank P Response N (%)a HR 95% CI Log-rank P
Age
 ≤ 58  yearsb 22/51 (43.1) 1.354 33/51 (64.7) 1.119
 > 58 years 34/58 (58.6) 1.000 0.430–1.269 0.265 40/58 (69.0) 1.000 0.465–1.718 0.734
Gender
 Female 17/22 (77.3) 1.000 18/22 (81.8) 1.000
 Male 39/87 (44.8) 3.230 0.122–0.780 0.004 55/87 (63.2) 2.664 0.132–1.064 0.038
Status in the Karnofsky scale
 ≤ 80% 21/49 (42.9) 1.712 29/49 (59.2) 1.912
 > 80% 35/60 (58.3) 1.000 0.340–1.004 0.051 44/60 (73.3) 1.000 0.271–1.011 0.052
Localization
 Oral cavity 10/24 (41.7) 5.962 0.781–45.497 15/24 (62.5) 2.034 0.439–9.418
 Oropharynx 34/68 (50.0) 4.458 0.614–32.829 48/68 (70.6) 1.329 0.310–5.693
 Hypopharynx 3/7 (42.9) 5.118 0.568–46.127 2/7 (28.6) 4.469 0.832–24.006
 Larynx 9/10 (90.0) 1.000 0.253 8/10 (80.0) 1.000 0.082
T stage
 1 + 2 18/26 (69.2) 1.000 22/26 (84.6) 1.000
 3 + 4 38/83 (45.8) 2.242 1.055–4.763 0.021 51/83 (61.4) 3.148 1.111–8.914 0.015
N stage
 0 + 1 23/37 (62.2) 1.000 27/37 (73.0) 1.000
 2 + 3 33/72 (45.8) 1.902 1.029–3.515 0.030 46/72 (63.9) 1.652 0.795–3.432 0.158
Grade
 1 + 2 53/96 (55.2) 1.000 68/96 (70.8) 1.000
 3 3/13 (23.1) 1.625 0.816–3.234 0.149 5/13 (38.5) 2.197 0.999–4.832 0.046
Keratinization
 Yes 27/62 (43.6) 1.734 38/62 (61.3) 1.863
 No 29/47 (61.7) 1.000 0.981–3.065 0.051 35/47 (74.5) 1.000 0.931–3.730 0.069
The level of smoking—Brinkman  indexc
 ≤  520b 32/54 (59.3) 1.000 42/54 (77.8) 1.000
 > 520 24/55 (43.6) 1.646 0.951–2.848 0.070 31/55 (56.4) 2.420 1.208–4.850 0.010
The level of  drinkingd
 Low 29/50 (58.0) 1.000 38/50 (76.0) 1.000
 High 27/59 (45.8) 1.588 0.914–2.760 0.094 35/59 (59.3) 2.106 1.051–4.221 0.030
HPV16 infection
 Present 23/36 (63.9) 1.000 30/36 (83.3) 1.000
 Absent 33/73 (45.2) 1.844 0.290–1.015 0.041 43/73 (58.9) 3.128 0.133–0.769 0.005
Treatment
 Definitive CRT or sur-
gery + CRT
31/46 (67.4) 1.000 35/46 (76.1) 1.000
 Definitive RT or surgery + RT 16/38 (42.1) 1.778 0.919–3.439 25/38 (65.8) 1.531 0.686–3.418
 Induction CT + definitive RT 9/25 (36.0) 2.460 1.212–4.994 0.050 13/25 (52.0) 2.405 1.058–5.470 0.103
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reproducible standard curves (Roberts et al. 2008) or sample 
bias related to tumour “purity”, i.e. proportion of tumour 
cells to normal cells within sample, which can influence 
genetic analysis (Aran et al. 2015). Another explanation 
might be the use of fresh (Mellin et al. 2002; Worden et al. 
2008) or archival, fixed material (Cohen et al. 2008; Huang 
et al. 2014). On the other hand, in our study, like in many 
other research works (Mellin et al. 2002; Cohen et al. 2008; 
Worden et al. 2008), VL is expressed as the number of viral 
genome copies per single cell, which allows to avoid discrep-
ancies related to the quality of samples. Another controversy 
is related to the heterogeneity of analysed HNSCC patient 
group according to treatment type. In our study, patients with 
high VL were statistically significantly more often treated 
with cisplatin-based chemoradiotherapy (post-operative or 
independent) than patients having tumours with lower VL 
(Table 2). However, we did not decide to analyse the influ-
ence of treatment type on prognostic potential of VL due 
to the low number of cases in each subgroup. According to 
our best knowledge, there are also no data in the worldwide 
literature concerning this question in HNSCC patients. The 
study of Worden et al. (2008) included two subgroups of 
patients: one treated with induction chemotherapy followed 
by chemoradiotherapy and the second, in which, after induc-
tion chemotherapy and surgery, adjuvant radiotherapy was 
applied. In turn, Huang et al. (2014) analysed prognostic 
power of VL in the group of patients treated with radical 
surgery with or without adjuvant therapy (radiotherapy or 
chemoradiotherapy). In both these studies, prognostic power 
of VL was analysed irrespective of treatment type. Further-
more, the influence of treatment type was not the subject of 
analysis. Because high VL may reflect active HPV infection, 
we additionally reviewed available meta-analyses (Ragin and 
Taioli 2007; Dayyani et al. 2010; O’Rorke et al. 2012; Liu 
et al. 2016) in respect of testing the relation between prog-
nostic significance of HPV presence and therapy regimens. 
In all meta-analyses, this relation was not tested, although 
all of them included studies involving different form of 
treatment (surgery alone or combination of surgery with 
induction or adjuvant radiotherapy or chemoradiotherapy). 
However, O’Rorke et al. (2012), discussing the results pre-
sented in their paper stated that the form of therapy may be 
one of the parameters confounding independence of HPV 
presence as risk factors. Taking all these facts into account, 
we think that VL has the potential to be reliable prognostic 
biomarker, although it requires validation in adequately large 
and homogeneous group of HNSCC patients according to 
tumour localization and treatment type.
Expression of P16 is a known surrogate marker of HPV 
infection (Serrano 1997). However, in the present paper 
we decided to analyse P16 immunostaining only in the 
subgroup of HPV16-positive tumours (identified on the 
basis of E6 gene fragment amplification). The main reason 
for this decision is relative low specificity of P16 expres-
sion analysis which generates risk of false positive results 
(Prigge et al. 2017). In the subgroup of 36 HPV16-positive 
tumours, we identified 9 tissues with lack of protein over-
expression and all these samples were characterized by 
lower VL (≤ 6764.3 copies/cell) (Table 2). On the con-
trary, among 25 cancers with P16 overexpression, there 
were 7 characterized by lower VL. These observations may 
be explained by the fact that overproduction of P16 can be 
caused not only by HPV infection, but also by oncogenes 
activation, DNA damage or accelerated cellular senes-
cence (Li et al. 2011). In turn, genetic alteration of P16 
gene (deletion, methylation and point mutation), found in 
nearly 50% of malignancies, can inhibit synthesis of this 
protein (Li et al. 2011). Probably for these reasons, in the 
Table 4  Multivariate Cox proportional hazard model
HR hazard ratio, CI confidence interval
a P value was examined by the Cox proportional hazard model for 
multivariate survival analysis
b Number of cigarettes per day × years of smoking
c Median value




  Male 3.461 0.114–0.732 0.009
 N stage
  0 + 1 1.000
  2 + 3 2.221 1.187–4.157 0.013
 HPV16 infection
  Present 1.000




  3 + 4 3.229 1.137–9.170 0.028
 The level of smoking—Brinkman  indexb
  ≤  520c 1.000
  > 520 2.149 1.069–4.319 0.032
 HPV16 infection
  Present 1.000
  Absent 3.083 0.134–0.783 0.012
Disease-free survival—36 patients with HPV16 positivity (assessed 
by amplification of viral gene E6 fragment)
 The level of smoking—Brinkman  indexb
  ≤  520c 1.000
  > 520 2.253 1.124–4.514 0.023
 Viral load
  > 6764.3 copies/cellc 1.000
  ≤ 6764.3 copies/cell 2.795 1.060–1.121 0.045
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present paper P16 expression proved to be weaker prog-
nostic marker than VL (Table 3). This finding is in line 
with those reported by other authors who have shown the 
best stratification of HNSCC patients with HPV positivity 
on the basis of VL and viral RNA expression (Jung et al. 
2010; Holzinger et al. 2012).
Our results suggest that the better survival for HPV16-
positive HNSCC patients is the effect of excellent prog-
nosis of patients with higher viral load, which is probably 
related to transcriptionally active infection and stimula-
tion of strong immune response. However, this assumption 
requires confirmation in further studies. Among HPV16-
positive patients, viral load has stronger prognostic poten-
tial than P16 expression.
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Fig. 2  Correlations between HPV16 load (VL—the number of 
HPV16 copies per single cell) and overall survival (a) and disease-
free survival (b) and between P16 expression and overall survival 
(c) and disease-free survival (d) in the subgroup of 36 patients with 
head and neck cancers with HPV16 positivity. Numbers in parenthe-
ses indicate the number of alive/dead patients or those with tumour 
regression/progression
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